Samsung Biologics Announces Preliminary Q2 2026 Results Sales Up 30.2% Operating Profit Up 22.9%
Samsung Biologics reported preliminary consolidated Q2 2026 results with sales of KRW 1,320.9 billion up 30.2% year-on-year and operating profit of KRW 586.4 billion up 22.9% year-on-year.
Net income was KRW 430.7 billion up 29.1% year-on-year. Compared to the previous quarter, sales increased 5.1% and operating profit increased 1.0% but net income decreased 8.2%.
These results are preliminary and subject to change after external audit review. Related materials will be posted on the company website.
[AI Summary]Samsung Biologics Q2 2026 results showed solid double-digit growth in sales and operating profit year-on-year, demonstrating continued operational strength. No capital changes or dividend information were disclosed. The stock price impact is expected to be neutral.